Clinical Trial: A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors

U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07811037) titled 'A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors' on Aug. 17.

Brief Summary: A Phase I/IIa clinical study SGT003 in patients with advanced solid tumors.

Study Start Date: Aug. 17

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumor

Intervention: DRUG: SGT003

Dosage Form: Injection

Strength: 50 mg (5 mL) per vial

Dosage and Administration: Subjects will receive SGT003 (investigational product) via intravenous (IV) infusion on Day 1 (D1) of each cycle. Dose: During the Phase I dos...